SYNCROSOME is proud to announce that it has joined the ETAP-Lab group, an offshoot of the preclinical CRO ETAP-Lab.
🚀 This acquisition marks a new stage in the company’s development.
Since its inception in 2000, SYNCROSOME has established itself as a key player in French preclinical research. By joining the ETAP-Lab group, SYNCROSOME is now bringing its expertise and innovative models to the in vivo evaluation of therapeutic strategy efficacy in cardiorespiratory medicine. SYNCROSOME’s expertise will also bolster ETAP-Lab’s historical activity in the field of neurology.
Given the synergies in terms of skills, technologies and scientific networks, this coming-together of the two laboratories will also strengthen the overall capabilities of the ETAP-Lab group. Moreover, SYNCROSOME will be able to draw on the scientific, technical, commercial and legal support of the ETAP-Lab group to accelerate development in its core areas of excellence, in line with the group’s overall strategy.
Nicolas Violle, now CEO of both SYNCROSOME and ETAP-Lab, said: “I am especially pleased to be working with Sandra Robelet and her team of scientists, whose expertise has consistently impressed me during the year we spent preparing this acquisition. I am also very confident that SYNCROSOME will be successfully integrated into the vision and growth strategy of the ETAP-Lab Group.”
To find out more, please read our official press release.
Keep an eye on our feed to hear all about this new adventure!
